<DOC>
	<DOCNO>NCT02725424</DOCNO>
	<brief_summary>This randomize , phase II , open-label study , The purpose study determine optimal treatment patient locally advanced Gastric/Gastroesophageal Cancer accord Her-2 expression status . The primary endpoint study : pathology response rate second endpoint study : pathology complete response rate R0 resection rate Progression-free survival ( PFS ) Disease -free survival ( DFS ) Overall survival ( OS ) Objective response rate ( ORR ) Adverse event ( AE )</brief_summary>
	<brief_title>Optimizing Strategy Preoperative Chemotherapy Locally Advanced Gastric/Gastroesophageal Cancer</brief_title>
	<detailed_description>( human epidermal growth factor receptor-2 , HER2 ) positive patient : After 4 week SOX±Trastuzumab Neoadjuvant therapy , show CR ( complete response ) PR ( partial response ) Resist evaluation continue D2 surgery , 4cycles SOX±Trastuzumab Adjuvant chemotherapy , 4cycles Trastuzumab maintenance therapy ; response former therapy progress , treat surgery , concurrent chemoradiotherapy , 2th line chemotherapy . ( human epidermal growth factor receptor-2 , HER2 ) negative patients： After 4 week DOS SOX regimen neoadjuvant therapy , show CR ( complete response ) PR ( partial response ) Resist evaluation continue D2 surgery , 4cycles SOX adjuvant chemotherapy , response former therapy progress , treat surgery , concurrent chemoradiotherapy , 2th line chemotherapy .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Inclusion criterion : 1 . Pathologically confirm gastric cancer gastroesophageal junction adenocarcinoma 2 . Significant HER2 status : positive define : immunohistochemistry+ + + FISH（fluorescence situ hybridization） + . T negative define : immunohistochemistry 0 ~ + , immunohistochemistry++ , FISH negative . 3 . T34 , N stage gastric cancer gastro esophageal carcinoma ( seventh edition AJCC ) . 4 . Chemotherapy radiotherapy naïve . 5 . Aging 1870 . 6 . ECOG ( Eastern Cooperative Oncology Group ) 01 7 . Available Organ function : Neutrophils &gt; 2g/L， Hemoglobin &gt; 9g/L， Blood platelet &gt; 100g/L； Alanine aminotransferase（ALT） Aspartate aminotransferase ( AST ) &lt; 1.5 ULN ( upper limit normal ) ； Total bilirubin ( TBIL ) &lt; 1.0 ULN ; Cr &lt; 1.0 ULN 8 . Left ventricular ejection fraction &gt; 50 % 9 . Written informed consent . Exclusion criterion : 1 . Other pathology Type Other adenocarcinoma , squamous cell carcinoma 2 . History allergy drug study 3 . Intraperitoneal dissemination distant metastasis 4 . Digestive tract obstruction uncontrollable recurrent bleeding , clinical significant ascites 5 . Dysphagia 6 . Any cause cirrhosis 7 . Cardiac function NYHA ( New York Heart Association ) &gt; I degrees 8 . Previous myocardial infarction , unstable angina , stroke , uncontrollable Arrhythmia 9 . Any surgical contraindication 10 . Any chemotherapy radiotherapy history 11 . Any surgical resection history gastric cancer 12 . History tumor except cure cutaneum carcinoma carcinoma situs cervix 13 . Any contraindication chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>